Small Cell Lung Cancer PDX Model: MSK-LX40-R

MSK-LX40-R

Small Cell Lung Cancer PDX Model: MSK-LX40-R

MSK-LX40-R
Share
Share

Sex: Male

Histology: Small cell lung cancer

Key Mutations: TP53 H179R, RB1 S567*, NOTCH1 P2Rfs*31,

MYCL Amplified

Molecular Characteristics: MSK-IMPACT, whole exome sequencing

Matched Normal: Yes

Treatment: LDE225 + cisplatin + etoposide, extensive cisplatin and

etoposide treatment in PDX

Site: Lung

Paired: Yes

Comments: Chemoresistant

Licensing Information: Corporations and other for-profit entities may nonexclusively license Memorial Sloan Kettering’s tangible materials for research or commercial purposes. For more information, please contact [email protected].

Stage of Development

Ready to use

Indications